What EyePoint Pharmaceuticals, Inc. told the SEC could break it.

EyePoint's manufacturing operations depend on its Watertown, MA and Northbridge, MA facilities — including the Class 10,000 clean rooms for DURAVYU Phase 3 clinical-trial material and the new Northbridge cGMP commercial facility. It states that if either location is destroyed or out of operation, its business may be adversely impacted. With production concentrated at these two single-state sites (and tech transfer of DURAVYU from Watertown to Northbridge underway), a fire, natural disaster, equipment failure, or regulatory shutdown at either site could halt clinical or commercial supply. A single-state, two-site manufacturing concentration.

“Our manufacturing operations currently depend on our Watertown, MA and Northbridge, MA facilities. If either location is destroyed or out of operation, our business may be adversely impacted.”

EyePoint's entire commercial future hinges on its lead candidate DURAVYU (vorolanib in Durasert E), and the development of DURAVYU is dependent on its supply of API vorolanib, which it currently sources from a sole supplier. It has not yet entered a long-term commercial supply agreement for vorolanib; if the sole supplier (or a licensing partner) fails to supply vorolanib in required amounts on time and on acceptable terms, or the arrangement is terminated, EyePoint could lose API supply or license rights material to its business and delay DURAVYU's Phase 3 program/commercial launch. Supplier unnamed, so a sole-source/API-concentration risk (the named YUTIQ API supplier Farmabios is captured as an edge).

“The development of our lead product candidate, DURAVYU, is dependent on our supply of API vorolanib, which we currently source from a sole supplier.”

Because some of EyePoint's manufacturers and suppliers are located in China and other foreign countries, it is exposed to product-supply disruption and increased costs from changes in U.S. (or foreign) trade policy — including recent import restrictions, increased tariffs, and changes in U.S. participation in trade agreements — as well as political/economic instability abroad. Tariff increases or trade restrictions on foreign-sourced API/components could raise costs or interrupt supply for its products and DURAVYU program. A trade-policy/tariff exposure on its foreign supply chain.

“Because some of our manufacturers and suppliers are located in China and other foreign countries, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies, laws, rules and regulations of the United States or foreign governments”